Table 2.
Pairwise comparisons of pathological complete response among the 16 treatments.
| PA-based +Cb+anti-PD-1 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 .34-5.53 |
PA-based +Cb+Bev | ||||||||||||||
| 1.91 .51-7.25 |
1.39 .44-4.36 |
PA-based +Cb+Veliparib | |||||||||||||
| 1.93 .30-12.40 |
1.40 .26-7.59 |
1.01 .20-5.03 |
PA-based +Cisplatin | ||||||||||||
| 2.23 .80-6.24 |
1.61 .64-4.09 |
1.16 .50-2.71 |
1.15 .25-5.44 |
PA-based +Cb | |||||||||||
| 2.44 .48-12.30 |
1.77 .37-8.38 |
1.27 .28-5.76 |
1.26 .17-9.24 |
1.09 .31-3.81 |
DCb | ||||||||||
| 2.52 .63-10.07 |
1.82 .84-3.93 |
1.31 .42-4.13 |
1.30 .24-7.07 |
1.13 .45-2.86 |
1.03 .22-4.89 |
PA-based +Bev | |||||||||
| 2.55 .46-13.99 |
1.84 .36-9.56 |
1.33 .27-6.58 |
1.32 .17-10.35 |
1.14 .29-4.44 |
1.04 .17-6.60 |
1.01 .20-5.24 |
PA-based +Olaparib | ||||||||
| 3.03 .70-13.06 |
2.19 .63-7.59 |
1.58 .52-4.86 |
1.57 .31-8.04 |
1.36 .48-3.84 |
1.24 .24-6.30 |
1.20 .35-4.16 |
1.19 .22-6.56 |
PCb | |||||||
| 4.86 .78-30.46 |
3.52 .67-18.60 |
2.54 .52-12.30 |
2.52 .35-18.15 |
2.18 .48-9.96 |
1.99 .28-14.24 |
1.93 .37-10.20 |
1.91 .25-14.63 |
1.61 .32-7.99 |
nabPA-based
+anti-PD-L1 |
||||||
| 5.42 .64-45.53 |
3.92 .54-28.52 |
2.83 .42-19.14 |
2.81 .30-26.64 |
2.43 .38-15.67 |
2.22 .24-20.92 |
2.15 .30-15.64 |
2.13 .21-21.32 |
1.79 .26-12.38 |
1.11 .38-3.28 |
nabPCb | |||||
| 5.92 .51-68.61 |
4.29 .39-47.75 |
3.09 .29-33.38 |
3.07 .20-46.09 |
2.66 .29-24.54 |
2.43 .39-15.28 |
2.35 .21-26.19 |
2.32 .17-31.44 |
1.96 .17-22.73 |
1.22 .08-17.99 |
1.09 .06-19.89 |
DA-based +Cb | ||||
|
4.58
1.37-15.37 |
3.32
1.31-8.42 |
2.39
1.11-5.14 |
2.37 .58-9.75 |
2.06 1.09-3.88 |
1.88 .46-7.63 |
1.82 .72-4.61 |
1.80 .40-8.05 |
1.51 .67-3.44 |
.94 .24-3.75 |
.85 .15-4.88 |
.77 .08-7.82 |
PA-based | |||
| 6.15 .77-48.87 |
4.45 .59-33.76 |
3.21 .44-23.45 |
3.19 .30-34.22 |
2.76 .46-16.68 |
2.52 .69-9.21 |
2.45 .32-18.52 |
2.42 .25-22.99 |
2.03 .25-16.20 |
1.27 .12-13.33 |
1.14 .09-15.14 |
1.04 .28-3.84 |
1.34 .20-9.04 |
DA-based | ||
|
7.04
1.67-29.68 |
5.10
1.51-17.17 |
3.68
1.23-10.96 |
3.65 .73-18.31 |
3.16
1.16-8.63 |
2.89 .58-14.34 |
2.80 .83-9.41 |
2.76 .51-14.96 |
2.32 .75-7.21 |
1.45 .46-4.52 |
1.30 .27-6.24 |
1.19 .10-13.64 |
1.54 .70-3.35 |
1.14 .15-8.98 |
nabPA-based | |
|
11.44
1.05-124.1 |
8.28 .87-79.03 |
5.98 .67-53.51 |
5.93 .49-71.72 |
5.13 .60-44.08 |
4.69 .39-56.37 |
4.55 .48-43.35 |
4.49 .35-57.10 |
3.78 .41-34.50 |
2.35 .51-10.78 |
2.11 .72-6.18 |
1.93 .09-42.58 |
2.50 .32-19.47 |
1.86 .11-30.68 |
1.62 .24-10.87 |
nabPGem |
Each cell represents the pairwise comparison of treatment in the column versus treatment in the row, which contains the odds ratio and its 95% confidence interval underneath.
Significant hazard ratios are in bold.
PA, pacalitaxel-anthracycle; PD-1, program death 1; Cb, carboplatin; Bev, bevacizumab; D, docetaxel; NabP, nab-paclitaxel; Gem, gemcitabine.